论文部分内容阅读
国外的研究表明,异搏定有良好的降血压效果和较少的副作用。不少人认为在未来十年里,异搏定将成为高血压病阶梯治疗方案中的一线药物。这方面国内研究尚不多。现将我们使用异搏定治疗高血压病的临床结果报告如下: 1.对象与方法:(1)高血压患者30例(男22,女8),年龄40～70岁(平均50.3)。按1979年郑州会议标准,Ⅰ期12例,Ⅱ期14例,Ⅲ期4例,30例中4例服用其它降压药效果不佳而改服异搏定。(2)治疗前病人停用降压药物两周以上。开始给异搏定80mg口服,每日三
Foreign studies have shown that verapamil has good antihypertensive effect and fewer side effects. Many people think that in the next decade, Verapamil will become the first-line drug in the treatment of hypertension ladder. There are not many domestic studies in this area yet. Now we use verapamil for the treatment of hypertension clinical results are reported as follows: 1. Subjects and Methods: (1) 30 cases of hypertensive patients (male 22, female 8), aged 40 to 70 years (mean 50.3). According to the standard of Zhengzhou Conference in 1979, 12 cases were stage Ⅰ, 14 cases were stage Ⅱ, 4 cases were stage Ⅲ, and 4 cases were treated with other antihypertensive drugs. (2) patients before treatment to disable antihypertensive drugs more than two weeks. Start to verapamil 80mg orally, three daily